Use of statins, amiodarone, direct oral anticoagulants and NSAIDs in chronic liver disease: a guide for general clinicians

1. ASRANI S., DEVARBHAVI H., EATON J., KAMATH P. Burden of liver diseases in the world. J Hepatol. 2019; 70(1):151–171.10.1016/j.jhep.2018.09.01430266282Search in Google Scholar

2. PIMPIN L., CORTEZ-PINTO H., NEGRO F. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018; 69(3):718–735.10.1016/j.jhep.2018.05.01129777749Search in Google Scholar

3. CHEDID, M. Nonalcoholic Steatohepatitis: The Second Leading Indication for Liver Transplantation in the USA. Dig Dis Sci. 2017; 62:2621–2622.10.1007/s10620-017-4724-628840385Search in Google Scholar

4. DOYCHEVA I., WATT K., RIFAI G. Increasing Burden of Chronic Liver Disease Among Adolescents and Young Adults in the USA: A Silent Epidemic. Dig Dis Sci. 2017; 62(5):1373–1380.10.1007/s10620-017-4492-328194666Search in Google Scholar

5. HEIDELBAUGH J., BRUDERLY M. Cirrhosis and chronic liver failure: Part I. Diagnosis and evaluation. Am Fam Physician. 2006; 74(5):756–762.Search in Google Scholar

6. YOUNOSSI Z., STEPANOVA M., YOUNOSSI Y., GOLABI P., MISHRA A., RAFIQ N., et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020; 69:564–568.10.1136/gutjnl-2019-31881331366455Search in Google Scholar

7. SCHIERWAGEN R., USCHNER F., MAGDALENO F., KLEIN S.,TREBICKA J. Rationale for the use of statins in liver disease. Am J Physiol Liver Physiol. 2017; 312:407–412.10.1152/ajpgi.00441.201628280144Search in Google Scholar

8. MOCTEZUMA-VELAZQUEZ C., ABRALDES J., MONTANO-LOZA A. The Use of Statins in Patients with Chronic Liver Disease. Curr Treat Options Gastro. 2018; 16:226–240.10.1007/s11938-018-0180-429572618Search in Google Scholar

9. VARGAS J., ARRESE M., SHAH V., ARAB J. Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects. Curr Gastroenterol Rep. 2017; 19(9):43.10.1007/s11894-017-0584-7582268628752475Search in Google Scholar

10. JANICKO M., DRAZILOVA S., PELLA D., FEDACKO J., JERCUSKA P. Pleiotropic effects of statins in the diseases of the liver. World J Gastroenterol. 2016; 22(27):6201–6213.10.3748/wjg.v22.i27.6201494597927468210Search in Google Scholar

11. KUMAR S., GRACE N., QAMAR A. Statin Use in Patients with Cirrhosis: A Retrospective Cohort Study. Dig Dis Sci. 2104; 59:1958–1965.10.1007/s10620-014-3179-224838495Search in Google Scholar

12. SAKAMOTO K., KIMURA J. Mechanism of Statin-Induced Rhabdomyolysis. J Pharmacol Sci. 2013; 123:289–294.10.1254/jphs.13R06CP24257439Search in Google Scholar

13. FARIGON, S., PORZIO, M., FRACANZANI A. Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. World J Gastroenterol. 2014; 20(37)13306–13324.10.3748/wjg.v20.i37.13306418888825309067Search in Google Scholar

14. DONGIOVANNI P., PETTA A., MANNISTRO V., MANCINA R., PIPITONE R., VALENTI L., et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. Journal of Hepatology. 2015; 63:705–712.10.1016/j.jhep.2015.05.00625980762Search in Google Scholar

15. IKEDA M., ABEK., YAMADA M., DANSAKO H., KATO N. Different anti-HCV profiles for statins and their potential for combination therapy with interferon. Hepatology. 2006; 44(1):117–125.10.1002/hep.2123216799963Search in Google Scholar

16. ABRALDES, J., VILLANUEVA C., ARACIL C., TURNES J., HERNANDEZ-GUERRA M., et a;. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. Gastroenterology. 2016; 150:1160–1170.10.1053/j.gastro.2016.01.00426774179Search in Google Scholar

17. SIMON T., BONILLA H., CHUNG R., BUTT A. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients hepatitis c virus: results from ERCHIVES. Hepatology. 2016; 64(1):47–57.10.1002/hep.28506491743826891205Search in Google Scholar

18. KAWATA S., YAMASAKI E., NAGASE T., INUI Y., ITO N., MATSUDA Y., et al. Effect of Pravastatin on Survival in Patients with Advanced Hepatocellular Carcinoma. A Randomized Control Trial.Br J Cancer. 2001; 84:886–891.10.1054/bjoc.2000.1716236383811286466Search in Google Scholar

19. CONNOLLY S. Evidence-based analysis of amiodarone efficacy and safety. Circulation. 1999; 100(19):2025.10.1161/01.CIR.100.19.202510556230Search in Google Scholar

20. BABATIN, M., LEE S., POLLAK P. Amiodarone Hepatotoxicity. Current Vascular Pharmacology. 2008; 6:228–236.10.2174/15701610878491201918673162Search in Google Scholar

21. POLLACK P., BOUILLON T., SHAFER S. Population pharmacokinetics of long-term oral amiodarone therapy. Clin Pharmacol Ther. 200; 67:642–652.10.1067/mcp.2000.10704710872646Search in Google Scholar

22. MATTAR W., GADUS-PIZLO I., KWO P. Amiodarone Hepatotoxicity in the Context of the Metabolic Syndrome and Right-sided Heart Failure. Gastrointestin Liver Dis. 2009; 18(4):419–423.Search in Google Scholar

23. PENDYALA V. A case of Amiodarone-induced Hepatitis and Review of the Literature. J Hepatol Gastroint Dis. 2016; 2:120.Search in Google Scholar

24. SUNG P., YOON S. Amiodarone Hepatotoxicity. Hepatology. 2012; 1:326.Search in Google Scholar

25. LEWIS J., RANARD R., CARUSO A., JACKSON L., MULLICK F., ISHAK K., et al. Amiodarone hepatotoxicity: prevalence and clincopathologic correlations among 104 patients. Hepatology. 1989; 9:679–685.10.1002/hep.18400905042785079Search in Google Scholar

26. ATIQ M., DAVIS J., LAMPS L., BLENAD S., ROSE L. Amiodarone induced liver cirrhosis, Report of two cases. J Gastrointestin Liver Dis. 2009; 18:233–235.Search in Google Scholar

27. GOLDSCHLAGER N., EPSTEIN A., NACCARELLI G., OLSHANSKY B., SINGHB. Practical guidelines for clinicians who treat patients with amiodarone. Practice guidelines subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med. 2000; 160:1741–1748.10.1001/archinte.160.12.174110871966Search in Google Scholar

28. KUM L., CHAN W., HUI H., WONG G., HO S., SANDERSON J., et al. Prevalence of amiodarone-related hepatotoxicity in 720 Chinese Patients with or without baseline liver dysfunction. Clin Cardiol. 2006; 29:295–299.10.1002/clc.4960290705665391216881537Search in Google Scholar

29. TRIPODI A., MUNUCCIP. The coagulopathy of chronic liver disease. N Engl J Med. 2011; 365:147–156.10.1056/NEJMra101117021751907Search in Google Scholar

30. QAMAR A., VADUGANATHAN M., GREENBERGER N., GIUGLIANO R. Oral anticoagulants in patients with liver disease. JAM Coll Cardiol. 2018; 71(19)2162–2175.10.1016/j.jacc.2018.03.02329747837Search in Google Scholar

31. LING K., CHAO T., LIU C., LIN Y., CHANG S., LO L., HU Y., TUAN, T., et al. Liver cirrhosis in patient with atrial fibrillation: would oral anticoagulation have a net clinical benefit for stroke prevention? J Am Herat Assoc. 2017; 6(6).10.1161/JAHA.116.005307566916228645935Search in Google Scholar

32. GORIACKO P. VELTRI K. Safety of direct oral anticoagulants vs warfarin in patients with chronic liver disease and atrial fibrillation. Eur J Haematol. 2018; 100(5):488–493.10.1111/ejh.1304529444357Search in Google Scholar

33. HUM J., SHATZEL J., JOU J., DELOUGHERY T. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol. 2017; 98:393–397.10.1111/ejh.1284428009449Search in Google Scholar

34. INTAGLIATA N., HENRY Z., MAITLAND H., SHAH N., MATILANDS H., SHAH N., ARGO C., NORTHUP P., CALDWELL S. Direct oral anticoagulants in cirrhosis patient pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci. 2016; 61:1721–1727.10.1007/s10620-015-4012-226725062Search in Google Scholar

35. MALESPIN M. Risk of nonsteroidal anti-inflammatory drugs and safety of acetaminophen in patients with advanced liver disease. Clin Liver Dis. 2018; 12(3):85–88.10.1002/cld.737638591330988918Search in Google Scholar

36. CHANDOK N., WATT K. Pain management in the cirrhotic patient: The clinical challenge. Mayo Clin Proc. 2010; 85(5):451–458.10.4065/mcp.2009.0534286197520357277Search in Google Scholar

37. Eliquis (apixaban) [package insert]. Bristol-Myers Squibb. New York, NY; 11/2019. [cited May 14/2020]. Available from: http://packageinserts.bms.com/pi/pi_eliquis.pdf.Search in Google Scholar

38. Pradaxa (dabigatran etexilate) [package insert]. Boehringer Ingelheim Pharmaceuticals Inc. Ridgefield, CT; 11/2019 [cited May 14, 2020]. Available from: https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf.Search in Google Scholar

39. Savaysa (edoxaban) [package insert]. Daiichi Sankyo. Tokyo, Japan. 1/2015 [cited May 14/2020]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf.Search in Google Scholar

40. Xarelto (rivaroxaban) [package insert]. Janssen Pharmaceuticals Inc. Titusville, NJ; 03/2020 [cited May 14/2020]. Available from: https://www.xareltohcp.com/shared/product/xarelto/prescribing-information.Search in Google Scholar